Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma

• Published in: European journal of medicinal chemistry Vol. 217; p. 113338
• Main Authors: Nepali, Kunal, Hsu, Tsung-I, Hsieh, Chien-Ming, Lo, Wei-Lun, Lai, Mei-Jung, Hsu, Kai-Cheng, Lin, Tony Eight, Chuang, Jian-Ying, Liou, Jing-Ping
• Format: Journal Article
• Language: English
• Published: ISSY-LES-MOULINEAUX Elsevier Masson SAS 05.05.2021; Elsevier
• Subjects: Chemistry, Medicinal; Glioblastoma; HDAC6; Hydroxamic acid; Life Sciences & Biomedicine; Linker; Memantine; Pharmacology & Pharmacy; Resistant; Science & Technology; Hydroxamic acid; Memantine; Resistant; Linker; HDAC6; Glioblastoma; STEM-CELLS; GLIOMA; RECURRENT GLIOBLASTOMA; BLOOD-BRAIN-BARRIER; MULTIFORME; ADJUVANT TEMOZOLOMIDE; PHASE-II TRIAL; IN-VITRO; TEMOZOLOMIDE RESISTANCE; ENHANCED EFFICACY
• ISSN: 0223-5234; 1768-3254
• DOI: 10.1016/j.ejmech.2021.113338

Hurdled and marred by the notorious nature of glioblastomas (GBM) in terms of resistance to therapy and limited drug delivery into the brain, the anti-GBM drug pipeline is required to be loaded with mechanistically diverse agents. The consideration of HDAC inhibition as a prudent approach to circumvent the resistance issue in GBM spurred us to pragmatically design and synthesizes hydroxamic acids endowed with CNS penetrating ability. By virtue of the blood brain barrier permeability (BBB), memantine was envisioned as an appropriate CAP component for the construction of the HDAC inhibitors. Diverse linkers were stapled for the tetheration of the zinc binding motif with the CAP group to pinpoint an appropriate combination (CAP and linker) that could confer inhibitory preference to HDAC6 isoform (overexpressed in GBM). Resultantly, hydroxamic acid 16 was identified as a promising compound that elicited striking antiproliferative effects against Human U87MG GBM cells as well as TMZ-resistant GBM cells and P1S cells, a concurrent chemo radiotherapy (CCRT)-resistant/patient-derived glioma cell line mediated through preferential HDAC6 inhibition (IC50 = 5.42 nM). Furthermore, 16 exerted cell cycle arrest at G2 phase, induced apoptosis in GBM cells at high concentration and exhibited high BBB permeability. To add on, in-vivo study revealed that the administration of compound 16 prolonged the survival of TMZ-resistant U87MG inoculated orthotopic mice. Overall, the cumulative results indicate that 16 is a tractable CNS penetrant preferential HDAC6 inhibitor that might emerge as a potent weapon against GBM. [Display omitted] •Memantine was employed as the CAP component for design of CNS penetrant HDAC inhibitors.•Compound 16 demonstrated striking antiproliferative effects against U87MG GBM cells as well as TMZ-resistant GBM cells.•Compound 16 exerted cell cycle arrest at G2 phase, induced apoptosis and exhibited high BBB permeability.•Compound 16 was identified as a preferential HDAC6 inhibitor.•Compound 16 prolonged the survival of TMZ-resistant U87MG inoculated orthotopic mice.